Arvaya Healthcare will acquire Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore via share swap. The company also approved a rights issue to raise up to ₹210 crore to fund expansion.
Arvaya Healthcare Expands with SIGPL Acquisition and Rights Issue
Arvaya Healthcare Ltd is set to acquire 100% of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 crore. The company also announced plans for a rights issue to raise up to ₹210 crore.
Reader Takeaway: Strategic healthcare acquisition faces related-party scrutiny; rights issue signals expansion.
What just happened
Arvaya Healthcare will acquire super-specialty gastroenterology hospital SIGPL for ₹15.49 crore. The deal will be settled by issuing 38.72 lakh equity shares at ₹40 each. Concurrently, the board approved a rights issue to raise a maximum of ₹210 crore.
The company is also relocating its registered office from Assam to Maharashtra.
Why this matters
The acquisition of SIGPL, a growing gastroenterology hospital, marks Arvaya Healthcare's strategic entry into the super-specialty healthcare segment. The planned capital raise of ₹210 crore indicates significant investment for future growth or financial restructuring.
The backstory
SIGPL, the target company, shows consistent revenue growth, with ₹6.36 crore in FY24, projected at ₹7.78 crore in FY25, and ₹8.99 crore in FY26. The acquisition price of ₹40 per share for SIGPL includes a ₹30 premium.
What changes now
Arvaya Healthcare will integrate SIGPL's operations to expand its diagnostic and hospital footprint. The rights issue, once finalized by a newly constituted committee, will infuse capital, potentially for further expansion or debt management.
Risks to watch
Investors should note the related-party nature of the SIGPL acquisition, involving Mr. Bidari Kotresh Anilkumar and Mr. Dhanaji Dattatray Jadhav. Such transactions require careful scrutiny for valuation and compliance. The issuance of new shares for the acquisition and the upcoming rights issue will lead to equity dilution.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
SIGPL Revenue:
- FY 2023-24: ₹6.36 crore
- FY 2024-25: ₹7.78 crore (projected)
- FY 2025-26: ₹8.99 crore (projected)
What to track next
Investors should closely monitor the final terms of the ₹210 crore rights issue, including the issue price and record date. Tracking the integration of SIGPL and its financial performance post-acquisition will also be crucial.